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BECAUTSE OF the neurotoxic side-effects of
the drugs currently available clinically to
sensitize hypoxic cells, it may be necessary
to restrict drug administration to a few of
the fractions in a course of radiotherapy.
The question immediately arises as to
whether it would be better to use the
sensitizer early in the treatment course, at
the end, or evenly spaced throughout. We
believe that it would be best to use the
drug at the beginning, for the reasons
outlined below:
If a tumour were completely hypoxic
and remained so throughout treatment the
sensitizer would be equally effective re-
gardless of when it was used. Similarly, if
the tumour contained a proportion of
hypoxic cells e.g. 10-20%, and these cells
did not change their oxygen status as
therapy progressed (i.e. no reoxygenation)
the sensitizer would be equally effective
with any fraction. This is illustrated
schematically in Fig. 1 for 1 fraction out of
7 given with sensitizer. The radiosensitive
oxic cells are readily killed and the hypoxic
cells dominate the response after a few
fractions. In this example an equal gain in
cell killing occurs if the sensitizer is given
with the first, middle or last dose.
However, most experimental tumours
show some reoxygenation of hypoxic cells
between fractions. If this is very effective
the tumour becomes more radiosensitive
and more curable. If it is only moderately
effective hypoxic cells remain and contri-
bute to the tumour bulk and hence growth,
either as persistent hypoxic cells or as
additional oxic cells (due to reoxygenation)
which cannot be killed because the toler-
ance dose for normal tissues canniot be
exceeded. In this situation the maximum
number of hypoxic cells is clearly present
on the first day of treatment and the
sensitizer will enhance the killing of the
maximum number of tumour cells at this
time. This is demonstrated in Figs. 2 and 3.
There is a large additional cell killing of
hypoxic cells if the sensitizer is added at
any time during the fractionated course.
Although the surviving number of hypoxic
cells is the same, 2a, regardless of whether
the sensitizer is used with the first 4 or the
last 4of8fractions, the number ofoxic cells
produced by reoxygenation and hence the
total number of cells surviving, 2c, is not
the same. In Fig. 2 a uniform rate or reoxy-
genation has been assumed, with 20% of
the hypoxic survivors at the end of each
fraction being reoxygenated before the
next dose. The same result is seen how-
ever, for a non-uniform rate ofreoxygena-
tion, for example reoxygenation occurring
during the later fractions, perhaps when
the tumour has started to shrink (Fig. 3).
In these examples, using only 8 small
daily fractions of 300 rad, half with and
half without sensitizer, there is a big
difference between no sensitizer and the 2
conditions with sensitizer, but a small
additional benefit is gained ifthe sensitizer
is given first. This benefit would of course
be amplified proportionally if, say, 20
fractions were given.
Stated simply, if any reoxygenation
occurs in a tumour the hypoxic cell
sensitizer should be used early in therapy,
when the maximum number of hypoxic
cells are available for sensitization. If noHYPOXIC CELL SENSITIZERS
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FIG. 1 Schematic survival curves for a mixed population of oxic and hypoxic cells treatedl with
multiple X-ray fractions. No re-oxygenation is assumed to occur.
(a) demonstrates that the small proportion of radioresistant hypoxic cells dominates the res-
ponse after a few fractions.
(b) (lemonstrates the same proportion of cell kill in the hypoxic population if a radiosensitizer is
used with any single fraction, whether early or late in the series.
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FIG. 2. Survival curves for a tumour containing 10% hypoxic cells, if the radiosensitizer is used with
the first 4 or the last 4 of 8 x 300 rad fractions. 20% of the hypoxic cells are assumed to reoxygenate
after each fraction.
(a) Hypoxic cells: the same cell kill is achieved whether the sensitizer is given fil-st or last.
(b) Oxic cells: these represent the survivors of each dose plus the contribution from hypoxic
cells due to reoxygenation. More cells survive if the sensitizer is given last than first.
(c) Total cells: oxic plus hypoxic survivors after reoxygenation. The most effective treatment is
when the sensitizer is given early in the treatment.
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FiG. 3.- Survival curves for a) hypoxic, b) oxic and c) total cells when reoxygenation is assumed to
occur only during the last 4 of 8 fractions. As in Fig. 2 the maximtum totail cell kill is achievedl when
the sensitizer is used early.
reoxygenation occurs, moreover, there is
no disadvantage in using the sensitizer at
this time. The only situation where this
rationale will not apply is if the tumour
continues to grow during therapy, so that
the number of hypoxic cells increases after
the first fraction. This is obviously a
hopeless situation anyway.
There may be two other advantages of
giving the sensitizer early. The use of
misonidazole as a radiosensitizer some-
times causes more rapid shrinkage of
mouse tumours (for the same amount of
growth delay) than is seen with X-rays
alone (Denekamp, unpublished). Rapid
tumour shrinkage may itself lead to more
effective reoxygenation, which would ren-
der the tumour more sensitive to the
subsequent X-ray doses (Dische, 1974;
Denekamp, 1977). Secondly, if direct
cytotoxicity to hypoxic cells is an import-
ant component of the effect of nitro-
imidazoles, early administration of the
drug would expose the maximum number
of hypoxic cells in the primary tumour to
its cytotoxic action, together with any
hypoxic foci in distant metastases at the
earliest possible phase of their growth.
In summary, the use of a hypoxic cell
sensitizer at the start oftherapy will be an
advantage in any tumour which reoxygen-
ates, and will be no disadvantage in a
tumour which does not. This rationale will
apply equally to any method designed to
kill hypoxic cells specifically, including the
electron-affinic radiosensitizers, high LET
radiation or hyperbaric oxygen.
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